Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.76 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11134095 | 0.94 | TAAR1 (0.73) | TAAR1AOC3SIGMAR1KCNH2HRH3 | |
| SCHEMBL11382868 | 0.89 | TAAR1 (0.61) | TAAR1AOC3SIGMAR1KCNH2HRH3 | |
| SCHEMBL9670561 | 0.89 | SIGMAR1 (0.64) | TAAR1AOC3SIGMAR1KCNH2HRH3 | |
| SCHEMBL3052863 | 0.86 | TAAR1 (1.00) | TAAR1AOC3SIGMAR1HRH3 | |
| Hydrochloric Acid SCHEMBL3820258 | 0.84 | TAAR1 (0.95) | TAAR1AOC3SIGMAR1HRH3 | |
| SCHEMBL9148552 | 0.82 | THRA (0.59) | TAAR1 | |
| SCHEMBL9671700 | 0.82 | HRH3 (0.74) | TAAR1AOC3SIGMAR1KCNH2HRH3 | |
| SCHEMBL9671267 | 0.81 | SIGMAR1 (0.75) | TAAR1SIGMAR1KCNH2HRH3 | |
| SCHEMBL14902842 | 0.80 | ALDH1A1 (0.56) | TAAR1SIGMAR1KCNH2HRH3 | |
| SCHEMBL19146986 | 0.80 | SIGMAR1 (0.55) | TAAR1AOC3SIGMAR1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946302-B2 | Selective sigma-1 receptor ligands | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130102571-A1 | SELECTIVE SIGMA-1 RECEPTOR LIGANDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-04-25 | — | — | US | disclosed |
| US-8349898-B2 | Sigma-1 receptor ligands and methods of use | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-20100179111-A1 | SIGMA-1 RECEPTOR LIGANDS AND METHODS OF USE | WARF - WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-4780478-A | Aminopropoxy-chromones useful as antidepressants | MERCK PATENT GESELLSCHAFT MIT BERSCHRANKTER HAFTUNG (DE) | 1988-10-25 | — | — | US | disclosed |
| US-4508732-A | Basic ethers useful as antidepressant agents | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1985-04-02 | — | — | US | disclosed |
| EP-0031885-B1 | BASIC ETHERS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR THEIR PREPARATION | MERCK PATENT GmbH (DE) | 1984-06-27 | — | — | EP | disclosed |
| US-4376123-A | Hexahydroazepinyloxy-chromones useful as antidepressants | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179111-A1 | SIGMA-1 RECEPTOR LIGANDS AND METHODS OF USE | SIGMAR1, OPRL1, OPRK1 | TAAR1 12/4885AOC3 1617/4885SIGMAR1 1/4885 |
| US-20130102571-A1 | SELECTIVE SIGMA-1 RECEPTOR LIGANDS | SIGMAR1, OPRL1, OPRK1 | TAAR1 15/4885AOC3 2023/4885SIGMAR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.